RCUS
Price:
$15.56
Market Cap:
$1.42B
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic can...[Read more]
Industry
Biotechnology
IPO Date
2018-03-15
Stock Exchange
NYSE
Ticker
RCUS
According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.28B. This represents a change of -0.74% compared to the average of 1.29B of the last 4 quarters.
The mean historical Enterprise Value of Arcus Biosciences, Inc. over the last ten years is 1.05B. The current 1.28B Enterprise Value has changed 12.06% with respect to the historical average. Over the past ten years (40 quarters), RCUS's Enterprise Value was at its highest in in the December 2021 quarter at 2.82B. The Enterprise Value was at its lowest in in the March 2018 quarter at -51615845.12.
Average
1.05B
Median
944.52M
Minimum
301.77M
Maximum
2.78B
Discovering the peaks and valleys of Arcus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 228.59%
Maximum Annual Enterprise Value = 2.78B
Minimum Annual Increase = -51.71%
Minimum Annual Enterprise Value = 301.77M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.30B | -7.52% |
2022 | 1.40B | -49.45% |
2021 | 2.78B | 119.55% |
2020 | 1.26B | 228.59% |
2019 | 384.71M | 27.48% |
2018 | 301.77M | -51.71% |
2017 | 624.93M | 77.40% |
The current Enterprise Value of Arcus Biosciences, Inc. (RCUS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
1.83B
5-year avg
1.42B
10-year avg
1.05B
Arcus Biosciences, Inc.’s Enterprise Value is greater than Cullinan Oncology, Inc. (810.70M), greater than Annexon, Inc. (621.99M), less than Structure Therapeutics Inc. (1.90B), greater than Relay Therapeutics, Inc. (867.37M), greater than Day One Biopharmaceuticals, Inc. (1.07B), greater than Acumen Pharmaceuticals, Inc. (137.49M), greater than X4 Pharmaceuticals, Inc. (20.60M), greater than Inozyme Pharma, Inc. (308.76M), greater than VectivBio Holding AG (848.58M), less than PTC Therapeutics, Inc. (2.85B), less than Blueprint Medicines Corporation (6.13B), less than Krystal Biotech, Inc. (4.54B), greater than Intercept Pharmaceuticals, Inc. (915.81M), less than Madrigal Pharmaceuticals, Inc. (6.99B), greater than Immix Biopharma, Inc. (20.49M), greater than CNS Pharmaceuticals, Inc. (2.61M), greater than Hepion Pharmaceuticals, Inc. (1.72M), greater than Freeline Therapeutics Holdings plc (2.82M), greater than AVROBIO, Inc. (-85302404.00), greater than Icosavax, Inc. (713.87M), less than Apellis Pharmaceuticals, Inc. (3.59B), greater than iTeos Therapeutics, Inc. (82.02M), greater than TScan Therapeutics, Inc. (116.95M),
Company | Enterprise Value | Market cap |
---|---|---|
810.70M | $922.99M | |
621.99M | $749.09M | |
1.90B | $2.27B | |
867.37M | $950.40M | |
1.07B | $1.49B | |
137.49M | $177.24M | |
20.60M | $89.59M | |
308.76M | $277.29M | |
848.58M | $1.06B | |
2.85B | $3.11B | |
6.13B | $5.84B | |
4.54B | $4.91B | |
915.81M | $794.69M | |
6.99B | $7.23B | |
20.49M | $43.37M | |
2.61M | $3.98M | |
1.72M | $3.68M | |
2.82M | $28.28M | |
-85302404.00 | $5.24M | |
713.87M | $769.04M | |
3.59B | $3.48B | |
82.02M | $327.60M | |
116.95M | $268.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Arcus Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 3-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 5-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
How does the current Enterprise Value for Arcus Biosciences, Inc. (RCUS) compare to its historical average?